Skip to Main Content
Contribute Try STAT+ Today

He was once dubbed “the most important man at Microsoft,” a prodigiously talented software engineer who shepherded the company’s Windows franchise through the tumultuous start of the smartphone era and led the development of products such as Xbox and Surface.

Now Terry Myerson is leading an equally bold — and treacherous — second act: He is the newly minted chief executive of Truveta, a company formed by 14 U.S. health systems to aggregate and sell de-identified data on millions of American patients to help answer some of medicine’s most pressing questions.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.